WO2004003145A3 - Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds - Google Patents

Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds Download PDF

Info

Publication number
WO2004003145A3
WO2004003145A3 PCT/US2003/019994 US0319994W WO2004003145A3 WO 2004003145 A3 WO2004003145 A3 WO 2004003145A3 US 0319994 W US0319994 W US 0319994W WO 2004003145 A3 WO2004003145 A3 WO 2004003145A3
Authority
WO
WIPO (PCT)
Prior art keywords
epithelial
compositions
methods
adhesion molecules
permeabilizing agent
Prior art date
Application number
PCT/US2003/019994
Other languages
French (fr)
Other versions
WO2004003145A2 (en
Inventor
Steven C Quay
Original Assignee
Nastech Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nastech Pharm Co filed Critical Nastech Pharm Co
Priority to EP03742185A priority Critical patent/EP1539208A2/en
Priority to JP2004517800A priority patent/JP2005537244A/en
Priority to AU2003279750A priority patent/AU2003279750A1/en
Priority to CA002487712A priority patent/CA2487712A1/en
Publication of WO2004003145A2 publication Critical patent/WO2004003145A2/en
Publication of WO2004003145A3 publication Critical patent/WO2004003145A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

Compositions and methods are provided that include a biologically active agent and a permeabilizing agent effective to enhance mucosal delivery of the biologically active agent in a mammalian subject. The permeabilizing agent reversibly enhances mucosal epithelial paracellular transport, typically by modulating epithelial junctional structure and/or physiology at a mucosal epithelial surface in the subject. This effect typically involves inhibition by the permeabilizing agent of homotypic or heterotypic binding between epithelial membrane adhesive proteins of neighboring epithelial cells. Target proteins for this blockade of homotypic or heterotypic binding can be selected from various related junctional adhesion molecules (JAMs), occludins, or claudins. The permeabilizing agent is typically a peptide or peptide analog or mimetic, often selected or derived from an extracellular domain of a mammalian JAM, occludin or claudin protein.
PCT/US2003/019994 2002-06-28 2003-06-24 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds WO2004003145A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP03742185A EP1539208A2 (en) 2002-06-28 2003-06-24 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
JP2004517800A JP2005537244A (en) 2002-06-28 2003-06-24 Compositions and methods for modulating physiological function of epithelial junction adhesion molecules for enhancing mucosal delivery of therapeutic compounds
AU2003279750A AU2003279750A1 (en) 2002-06-28 2003-06-24 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
CA002487712A CA2487712A1 (en) 2002-06-28 2003-06-24 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39251202P 2002-06-28 2002-06-28
US60/392,512 2002-06-28

Publications (2)

Publication Number Publication Date
WO2004003145A2 WO2004003145A2 (en) 2004-01-08
WO2004003145A3 true WO2004003145A3 (en) 2004-06-10

Family

ID=30000886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/019994 WO2004003145A2 (en) 2002-06-28 2003-06-24 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds

Country Status (7)

Country Link
US (1) US20040077540A1 (en)
EP (1) EP1539208A2 (en)
JP (1) JP2005537244A (en)
AU (1) AU2003279750A1 (en)
CA (1) CA2487712A1 (en)
WO (1) WO2004003145A2 (en)
ZA (1) ZA200410287B (en)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032410A1 (en) * 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
US7244703B2 (en) * 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
US20040254146A1 (en) * 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
AU2003248888A1 (en) * 2002-07-09 2004-01-23 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
JP4903036B2 (en) * 2003-01-06 2012-03-21 アンジオケム・インコーポレーテッド Aprotinin and analogs as carriers that cross the blood brain barrier
US20040258663A1 (en) * 2003-05-08 2004-12-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon alpha
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
WO2005016111A2 (en) 2003-08-08 2005-02-24 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
US20050129679A1 (en) * 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
RU2006143544A (en) * 2004-05-10 2008-06-20 Нэстек Фармасьютикал Кампани Инк. (Us) COMPOSITIONS AND METHOD FOR LIGHTENED TRANSMISSION DELIVERY OF PARATHYROID HORMONE
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
EP1768647B1 (en) * 2004-06-17 2012-08-08 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agent
US20060062758A1 (en) * 2004-09-21 2006-03-23 Nastech Pharmaceutical Comapny Inc. Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds
MX2007005790A (en) * 2004-11-16 2007-09-11 Limerick Neurosciences Inc Methods and compositions for treating pain.
US20070087977A1 (en) * 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
PL1859041T5 (en) * 2005-02-18 2015-05-29 Angiochem Inc Aprotinin polypeptides for transporting a compound across the blood-brain barrier
GB0509317D0 (en) * 2005-05-06 2005-06-15 Clarke Anthony Pharmaceutical formulation of apomorphine
AU2006257792A1 (en) * 2005-06-13 2006-12-21 Mdrna, Inc. Transmucosal delivery of peptide derivatives
EP2471555A3 (en) 2005-07-15 2012-10-17 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
US20090220435A1 (en) 2005-07-27 2009-09-03 Nastech Pharmaceutical Company Inc. Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20070154449A1 (en) * 2005-12-16 2007-07-05 Nastech Pharmaceutical Company Inc. Tight junction modulating peptides for enhanced mucosal delivery of therapeutic compounds
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
US9023793B2 (en) 2006-09-29 2015-05-05 Retrophin, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
DK2148691T3 (en) 2007-02-05 2015-08-17 Apellis Pharmaceuticals Inc Compstatinanaloger for use in the treatment of inflammatory states of the respiratory system
US8512693B2 (en) * 2007-02-14 2013-08-20 Northwestern University Self-assembling membranes and related methods thereof
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
ES2539818T3 (en) * 2007-08-02 2015-07-06 Biondvax Pharmaceuticals Ltd. Multimeric multi-epitopic flu vaccines
WO2009027697A2 (en) * 2007-08-31 2009-03-05 Archimedes Development Limited Non-aqueous pharmaceutical compositions
EP2030610A1 (en) * 2007-08-31 2009-03-04 Archimedes Development Limited Non-aqueous pharmaceutical compositions
US9540649B2 (en) 2007-10-12 2017-01-10 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Method for opening tight junctions
WO2009049365A1 (en) * 2007-10-15 2009-04-23 Cooperative Research Centre For Asthma A method of prophylaxis and agents for use therein
RU2518240C2 (en) * 2008-04-18 2014-06-10 Ангиочем Инк. Composition based on hydrophobic agents and method for preparing it (versions)
EP2346896A4 (en) 2008-10-15 2014-06-25 Angiochem Inc Etoposide and doxorubicin conjugates for drug delivery
US8921314B2 (en) 2008-10-15 2014-12-30 Angiochem, Inc. Conjugates of GLP-1 agonists and uses thereof
CA2745524C (en) * 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
MX2011006685A (en) 2008-12-17 2011-09-27 Angiochem Inc Membrane type-1 matrix metalloprotein inhibitors and uses thereof.
US20120058956A1 (en) * 2009-03-03 2012-03-08 Metamorefix Ltd. Peptides derived from ficolin as surfactants
JP2012520686A (en) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション RNA interference-mediated inhibition of signal transduction transcription factor 6 (STAT6) gene expression using small interfering nucleic acids (siNA)
US20120016011A1 (en) 2009-03-19 2012-01-19 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010107957A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
MX2011009724A (en) 2009-03-19 2011-10-14 Merck Sharp & Dohme RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING.
JP2012521762A (en) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション RNA interference-mediated inhibition of nerve growth factor β chain (NGFβ) gene expression using small interfering nucleic acids (siNA)
EP2411019A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111497A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111490A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof
US8263581B2 (en) * 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
WO2011128884A1 (en) * 2010-04-11 2011-10-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Extract and peptides derived from oryza sativa japonica group and uses thereof
JP6043285B2 (en) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. RNA interference-mediated inhibition of catenin (cadherin-binding protein) β1 (CTNNB1) gene expression using small interfering nucleic acids (siNA)
LT2606134T (en) 2010-08-17 2019-07-25 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US9233997B2 (en) 2010-08-26 2016-01-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
CN103619879A (en) 2010-12-01 2014-03-05 奥尔德生物控股有限责任公司 Anti-ngf compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
DK2646035T3 (en) 2010-12-02 2016-05-30 Univ Kansas PRO-DRUGS OF 6-CYCLOHEXYL-1-HYDROXY-4-METHYLPYRIDINE-2 (1H) -ON AND DERIVATIVES THEREOF
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
EP2561886A1 (en) * 2011-08-23 2013-02-27 Forschungsverbund Berlin e.V. Peptide adjuvant for improved peripheral analgesia
BR112014014868B1 (en) * 2011-12-19 2022-12-27 Genzyme Corporation THYROID STIMULATING HORMONE COMPOSITIONS, METHODS OF PRODUCING THE SAME AND USE OF SUCH COMPOSITIONS
US20150031610A1 (en) * 2012-03-05 2015-01-29 Synedgen, Inc. Derivatized polyglucosamines for delivery of small molecules, peptides, and proteins
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
KR20150090917A (en) 2012-12-06 2015-08-06 머크 샤프 앤드 돔 코포레이션 Disulfide masked prodrug compositions and methods
CN103146779B (en) * 2013-04-02 2014-07-30 南京工业大学 Method of synthesizing trehalose by virtue of whole cell catalysis
US10426828B2 (en) 2014-04-03 2019-10-01 Biondvax Pharmaceuticals Ltd. Compositions of multimeric-multiepitope influenza polypeptides and their production
CN103923216B (en) * 2014-04-22 2016-04-27 吉林大学 Multifunction module fusion rotein and the application in raising protein drug oral administration biaavailability thereof
EP3145533A2 (en) 2014-05-23 2017-03-29 Reponex Pharmaceuticals APS Compositions for promoting the healing of wounds
EP3848047A1 (en) 2014-07-24 2021-07-14 Reponex Pharmaceuticals APS Compositions comprising granulocyte-macrophage colony-stimulating factor for the treatment of inflammatory bowel disease
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
DK3307326T3 (en) 2015-06-15 2020-10-19 Angiochem Inc METHODS FOR THE TREATMENT OF LEPTOMENINGAL CARCINOMATOSIS
EP3532031A4 (en) * 2016-10-26 2020-06-03 Revive Pharmaceuticals, LLC Treating sexual dysfunction
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US10738079B2 (en) * 2017-04-14 2020-08-11 Emory University Compositions and methods for managing respiratory conditions
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2019165346A1 (en) * 2018-02-23 2019-08-29 Innovate Biopharmaceuticals, Inc. Compounds and methods for treating tight junction permeability
JPWO2019221039A1 (en) * 2018-05-14 2021-05-13 公立大学法人福島県立医科大学 Cell culture aid
JP2021529220A (en) 2018-09-20 2021-10-28 リーヴォ セラピューティクス, インコーポレイテッド Stable intranasal preparation of carbetocin
KR20210062648A (en) 2018-09-20 2021-05-31 레보 테라퓨틱스 인코포레이티드 Carbetocin drug product and method of manufacturing the same
US10413556B1 (en) * 2019-03-21 2019-09-17 Moshe Shifrine Production of insulin by testosterone olfaction
EP3955936A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Treatment of depression and other various disorders with psilocybin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110747A (en) * 1997-12-31 2000-08-29 Adherex Technologies Inc. Compounds and methods for modulating tissue permeability

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5554388A (en) * 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
SE8904296D0 (en) * 1989-12-21 1989-12-21 Pharmacia Ab TRANSDERMAL SYSTEM
JPH0532696A (en) * 1990-09-28 1993-02-09 Takeda Chem Ind Ltd Parathyroid hormone derivative
JPH07503154A (en) * 1992-01-21 1995-04-06 エス・アール・アイ・インターナシヨナル Improved preparation method for miniaturized polypeptide drugs
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
TW460296B (en) * 1994-09-01 2001-10-21 Janssen Pharmaceutica Nv Topical ketoconazole emulsion compositions without sodium sulfite
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
EP0908181B8 (en) * 1996-05-20 2009-04-15 Otsuka Pharmaceutical Co., Ltd. Remedy for rosacea
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
AU751182B2 (en) * 1997-12-02 2002-08-08 Archimedes Development Limited Compositions for nasal administration
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US20030017497A1 (en) * 1998-02-04 2003-01-23 Thomas Kieber-Emmons Peptide mimotopes of carbohydrate antigens
US6960566B1 (en) * 1998-11-06 2005-11-01 The Wister Institute of Anatomy and Biology Compositions and methods for treatment of cancer
US6391855B1 (en) * 1999-06-02 2002-05-21 Adherex Technologies, Inc. Compounds and methods for modulating junctional adhesion molecule-mediated functions
CA2382783A1 (en) * 1999-08-24 2001-03-01 Texas Biotechnology Corporation A polynucleotide encoding a human junctional adhesion protein (jam-2)
GB9924797D0 (en) * 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US20040028613A1 (en) * 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
US20040258663A1 (en) * 2003-05-08 2004-12-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon alpha
US20060210614A1 (en) * 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110747A (en) * 1997-12-31 2000-08-29 Adherex Technologies Inc. Compounds and methods for modulating tissue permeability
US6248864B1 (en) * 1997-12-31 2001-06-19 Adherex Technologies, Inc. Compounds and methods and modulating tissue permeability

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AURRAND-LIONS ET AL.: "JAM-2, a novel immunoglobulin superfamily molecule, expressed by endothelial and lymphatic cells", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 4, 26 January 2001 (2001-01-26), pages 2733 - 2741, XP002972606 *

Also Published As

Publication number Publication date
AU2003279750A1 (en) 2004-01-19
CA2487712A1 (en) 2004-01-08
EP1539208A2 (en) 2005-06-15
JP2005537244A (en) 2005-12-08
US20040077540A1 (en) 2004-04-22
ZA200410287B (en) 2005-11-18
WO2004003145A2 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
WO2004003145A3 (en) Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
WO2006044596A8 (en) Multi-domain amphipathic helical peptides and methods of their use
EP2267027A3 (en) Method of administering therapeutic polypeptides, and polypeptides therefor
WO2006088508A3 (en) Cupredoxin derived transport agents and methods of use thereof
EP1900753A3 (en) Method of administering therapeutic polypeptides, and polypeptides therefor
AU2003266159A1 (en) System and method for delivering a composition to the nasal membrane
WO2007104062A3 (en) Compositions and methods based on peptide binding profiling
WO2009133137A3 (en) Pegylated recombinant human growth hormone compounds
MX2009013372A (en) Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (alpha-msh) and atrial natriuretic protein (anp) and uses in hypertension and acute kidney injury.
EP2409988A3 (en) Peptide fragments for inducing synthesis of extracellular matrix proteins
EP1137658A4 (en) METHODS OF MODULATING TUMOR NECROSIS FACTOR $g(a)-INDUCED EXPRESSION OF CELL ADHESION MOLECULES
AU2003261165A1 (en) Improved fuel delivery system
RS20070027A (en) Anti-cd154 antibodies
WO2007012004A3 (en) Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof
BRPI0513477A (en) Angiotensin-like protein 4 compositions and processes
AU2003222067A1 (en) System for delivery of therapeutic substances
IL147138A0 (en) Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
WO2003070892A3 (en) Inhibitors of rgs proteins
WO2009081368A3 (en) Cosmetic use desmoglein i-type proteins
WO2008103378A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
AU2003301444A1 (en) System for delivery of active substances
WO2007109648A3 (en) Compositions and methods for modulating store-operated calcium entry
WO2004112820A3 (en) Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity
AU2003272517A1 (en) Compositions to reduce congestion and methods for application thereof to the nasal membrane
EP1779860A3 (en) The chromatin peptides blocking human HIF-1a gene and modulating the downstream related genes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2487712

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 01951/KOLNP/2004

Country of ref document: IN

Ref document number: 1951/KOLNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004/10287

Country of ref document: ZA

Ref document number: 200410287

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2004517800

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003279750

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 537569

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003742185

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003742185

Country of ref document: EP